Peptide Evidence & Study Quality Hub
How to interpret published peptide research — from individual papers to the body of evidence behind a claim. Grading, translation, direct vs inferred combinations, and the common pitfalls that turn weak evidence into confident headlines.
Evidence grading methodology
The A-X grading system used across PeptideStacks, and how grades are assigned conservatively.
Animal vs human peptide research
Why rodent results rarely translate, dose-scaling problems, and species differences in pharmacology.
In vitro evidence limitations
Why a cell-line result is not a clinical claim, and the concentration-relevance problem.
Direct vs inferred combinations
Most 'stacks' are inferred from monotherapy studies — direct combination studies are rare.
How to read peptide studies
Study type, sample size, endpoints, blinding, conflicts of interest, and limitations — what to look for.
Human data vs preclinical data
A direct comparison of what each can and cannot tell you.
Claims with weak evidence
Common claim categories where the evidence base does not support the confidence of the claim.
Negative & null findings
Why no-result studies matter as much as positive ones, and how publication bias distorts the picture.
Allometric scaling failures
Why rodent doses in mg/kg don't convert cleanly to human doses — and why peptides translate especially poorly.
Time-dependent repair cascade
Days 0–7 angiogenesis → 7–21 proliferation → 3–12 weeks remodelling. The time-axis framework behind tissue-repair stacks.
Pages on PeptideStacks are reviewed when relevant new evidence becomes available. If you spot an error or have new evidence to suggest, please use our corrections policy.